此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis (REFINE)

2017年2月7日 更新者：Amgen

A Randomized, Blinded Assessor Study to Evaluate the Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent Versus Etanercept 50 mg Twice Weekly in Subjects With Moderate to Severe Plaque Psoriasis

To estimate the difference in effectiveness between treatment with etanercept 50 mg twice weekly (BIW) and treatment with etanercept 50 mg once weekly (QW) plus an as needed (PRN) topical agent for 12 weeks in adults with moderate to severe plaque psoriasis.

研究概览

地位

完全的

条件

干预/治疗

详细说明

The recommended starting dose of etanercept for adult plaque psoriasis patients is a 50 mg dose given twice a week (BIW) for 3 months followed by a reduction to a maintenance dose of 50 mg once weekly (QW). While most patients with moderate to severe plaque psoriasis are managed satisfactorily on etanercept monotherapy, a proportion may require a modified or alternative treatment regimen (eg, to handle flares or loss of effect) at some point during their chronic management. Despite the clinical need, no published data from randomized controlled studies are currently available that demonstrate efficacy and safety of combined etanercept-based regimens in patients with plaque psoriasis.

The addition of an as-needed topical medication to the step-down dose of etanercept 50 mg once weekly administered after the initial 12 week period of 50 mg twice weekly may be a potential option for patients who may require adjunctive therapy. This study aimed to provide data on this treatment option by estimating the difference in mean percent change in Psoriasis Area and Severity Index (PASI) scores between step-down etanercept 50 mg once weekly supplemented with as-needed topical medication and continuous treatment with etanercept 50 mg twice weekly.

Eligible patients will be enrolled in the study and will receive etanercept 50 mg twice weekly for 12 weeks. After 12 weeks of etanercept treatment, participants will be randomized in a 1:1 ratio to 1 of 2 treatment groups.

研究类型

介入性

注册 (实际的)

310

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 加拿大
      • Quebec、加拿大、G1V 4X7
        • Research Site
      • Quebec、加拿大、G1J 1X7
        • Research Site
    • Alberta
      • Calgary、Alberta、加拿大、T2G 1B1
        • Research Site
    • British Columbia
      • Surrey、British Columbia、加拿大、V3R 6A7
        • Research Site
      • Vancouver、British Columbia、加拿大、V5Z 4E8
        • Research Site
    • Manitoba
      • Winnipeg、Manitoba、加拿大、R3C 0N2
        • Research Site
    • New Brunswick
      • Moncton、New Brunswick、加拿大、E1C 8X3
        • Research Site
    • Newfoundland and Labrador
      • St. John's、Newfoundland and Labrador、加拿大、A1A 5E8
        • Research Site
      • St. John's、Newfoundland and Labrador、加拿大、A1C 2H5
        • Research Site
    • Nova Scotia
      • Halifax、Nova Scotia、加拿大、B3H 1Z4
        • Research Site
    • Ontario
      • Courtice、Ontario、加拿大、L1E 3C3
        • Research Site
      • Markham、Ontario、加拿大、L3P 1A8
        • Research Site
      • Mississauga、Ontario、加拿大、L5H 1G9
        • Research Site
      • North Bay、Ontario、加拿大、P1B 3Z7
        • Research Site
      • Peterborough、Ontario、加拿大、K9J 1Z2
        • Research Site
      • Richmond Hill、Ontario、加拿大、L4B 1A5
        • Research Site
      • Sudbury、Ontario、加拿大、P3C 1X8
        • Research Site
      • Toronto、Ontario、加拿大、M3H 5Y8
        • Research Site
      • Toronto、Ontario、加拿大、M4V 1R1
        • Research Site
      • Waterloo、Ontario、加拿大、N2J 1C4
        • Research Site
      • Windsor、Ontario、加拿大、N8W 5L7
        • Research Site
    • Quebec
      • Montreal、Quebec、加拿大、H2K 4L5
        • Research Site
      • Montreal、Quebec、加拿大、H3Z 2S6
        • Research Site
      • Saint-Hyacinthe、Quebec、加拿大、J2S 6L6
        • Research Site

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Has had stable moderate to severe plaque psoriasis for at least 6 months (eg, no morphology changes or significant flares of disease activity in the opinion of the investigator).
  • Has a body surface area (BSA) involvement ≥ 10% and Psoriasis Area and Severity Index (PASI) ≥ 10 at screening and at baseline.
  • Is a candidate for systemic therapy or phototherapy in the opinion of the investigator.
  • Other inclusion criteria may apply.

Exclusion Criteria:

  • Has active guttate, erythrodermic, or pustular psoriasis at the time of the screening visit.
  • Has evidence of skin conditions at the time of the screening visit (eg, eczema) that would interfere with evaluations of the effect of etanercept on psoriasis.
  • Diagnosed with medication-induced or medication-exacerbated psoriasis.
  • Significant concurrent medical conditions.
  • Has any active localized infection; requiring local intervention or chronic or localized infections.
  • Other exclusion criteria may apply.

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：单身的

武器和干预

参与者组/臂
干预/治疗
有源比较器：Etanercept 50 mg BIW
Following 12 weeks of etanercept 50 mg twice weekly, participants were randomized to 50 mg etanercept twice weekly for 12 weeks.
生物：etanercept
Administered by subcutaneous injection
其他名称：
  • 恩布雷
实验性的：Etanercept 50 mg QW + Topical
Following 12 weeks of etanercept 50 mg twice weekly, participants were randomized to 50 mg etanercept once weekly plus as needed topical agents.
生物：etanercept
Administered by subcutaneous injection
其他名称：
  • 恩布雷
药品：Topical agents

Topical agents prescribed at the discretion of the Principal Investigator and were are limited to the following:

  • hydrocortisone 2.5%
  • betamethasone valerate 0.1%
  • betamethasone dipropionate 0.05%
  • clobetasol 0.05%
  • calcitriol
  • calcipotriol plus betamethsone dipropionate 0.05%

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Percent Change in Psoriasis Area and Severity Index (PASI) From Week 12 to Week 24
大体时间：Week 12 and Week 24
The Psoriasis Area and Severity Index (PASI) score is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from none (0), mild (1), moderate (2), severe (3) or very severe (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Change from Week 12 to Week 24 is presented as a percentage of the Week 12 value: Week 12 value - Week 24 value / Week 12 value * 100 so that a positive change indicates improvement. Change was adjusted for treatment using a mixed model.
Week 12 and Week 24

次要结果测量

结果测量
措施说明
大体时间
Percent Change in PASI From Week 12 to Weeks 16 and 20
大体时间：Week 12, Week 16 and Week 20
The Psoriasis Area and Severity Index (PASI) score is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from none (0), mild (1), moderate (2), severe (3) or very severe (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Change from Week 12 presented as a percentage of the Week 12 value: Week 12 value - postbaseline value / Week 12 value * 100, so that a positive change indicates improvement. Change was adjusted for treatment using a mixed model.
Week 12, Week 16 and Week 20
Percent Change in PASI From Baseline to Weeks 12, 16, 20, and 24
大体时间：Baseline and Weeks 12, 16, 20, and 24
The Psoriasis Area and Severity Index (PASI) score is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from none (0), mild (1), moderate (2), severe (3) or very severe (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Change from Baseline is presented as a percentage of the Baseline value: Baseline value - postbaseline value / Baseline value * 100, so that a positive change indicates improvement.
Baseline and Weeks 12, 16, 20, and 24
Percentage of Participants With a PASI 50 Response
大体时间：Baseline and Weeks 12, 16, 20 and 24
The percentage of participants with a 50% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score is based on an assessment of erythema (reddening), induration (plaque thickness), desquamation (scaling), and the percent area affected as observed on the day of examination. The score ranges from 0 (best outcome) to 72 (worst outcome).
Baseline and Weeks 12, 16, 20 and 24
Percentage of Participants With a PASI 75 Response
大体时间：Baseline and Weeks 12, 16, 20 and 24
The percentage of participants with a 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score is based on an assessment of erythema (reddening), induration (plaque thickness), desquamation (scaling), and the percent area affected as observed on the day of examination. The score ranges from 0 (best outcome) to 72 (worst outcome).
Baseline and Weeks 12, 16, 20 and 24
Percentage of Participants With a PASI 90 Response
大体时间：Baseline and Weeks 12, 16, 20 and 24
The percentage of participants with a 90% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score is based on an assessment of erythema (reddening), induration (plaque thickness), desquamation (scaling), and the percent area affected as observed on the day of examination. The score ranges from 0 (best outcome) to 72 (worst outcome).
Baseline and Weeks 12, 16, 20 and 24
Percentage of Participants With a Static Physician's Global Assessment (sPGA) of Psoriasis Score of 0 (Clear) or 1 (Almost Clear)
大体时间：Weeks 12, 16, 20, and 24
The sPGA scale is completed by the same blinded assessor performing the PASI assessments and is designed to evaluate the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale of 0 to 5 (0 = clear, 5 = severe).
Weeks 12, 16, 20, and 24
Percent Change in the Percentage of Body Surface Area (BSA) Involvement From Week 12 to Weeks 16, 20, and 24
大体时间：Weeks 12, 16, 20, and 24

The percentage of body surface area involved with psoriasis was measured by the same blinded assessor performing the PASI assessments. Change from Week 12 is presented as a percentage of the Week 12 value: Week 12 value - postbaseline value / Week 12 value * 100, so that a positive change indicates improvement.

Change was adjusted for treatment using a mixed model.
Weeks 12, 16, 20, and 24
Percent Change in the Percentage of Body Surface Area (BSA) Involvement From Baseline to Weeks 12, 16, 20, and 24
大体时间：Baseline and Weeks 12, 16, 20, and 24

The percentage of body surface area involved with psoriasis was measured by the same blinded assessor performing the PASI assessments.

Change from Baseline \ is presented as a percentage of the Baseline value: Baseline value - postbaseline value / Baseline value * 100, so that a positive change indicates improvement.
Baseline and Weeks 12, 16, 20, and 24
Change From Week 12 to Week 24 in Dermatology Quality of Life Index (DQLI) Total Score
大体时间：Week 12 and Week 24
The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. Change from Week 12 to Week 24 is calculated as: Week 12 value - Week 24 value so that a positive change indicates improvement. Change was adjusted for treatment using a mixed model.
Week 12 and Week 24
Change From Baseline to Weeks 12 and 24 in Dermatology Quality of Life Index (DQLI) Total Score
大体时间：Baseline and Week 12 and Week 24
The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. Change from Baseline was calculated as Baseline value - postbaseline value so that a positive change indicates improvement.
Baseline and Week 12 and Week 24
Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Week 12 to Week 24
大体时间：Week 12 and Week 24
TSQM is a validated questionnaire consisting of 14 questions regarding a participant's perception of the level of satisfaction or dissatisfaction with the medication they are taking. Four scales are generated: side effects, effectiveness, convenience, and global satisfaction. Optional responses are: Extremely Dissatisfied, Very Dissatisfied, Dissatisfied, Somewhat Satisfied, Satisfied, Very Satisfied, and Extremely Satisfied. From the responses, a scale score from 0 - 100 is calculated, with a higher score indicating greater satisfaction. Change was calculated as Week 24 - Week 12 so that a positive change indicates improvement over time. Change was adjusted for treatment using a mixed model.
Week 12 and Week 24
Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Baseline to Weeks 12 and 24
大体时间：Baseline and Weeks 12 and 24
The TSQM is a validated questionnaire consisting of 14 questions regarding a participant's perception of the level of satisfaction or dissatisfaction with the medication they are taking. Four scales are generated: side effects, effectiveness, convenience, and global satisfaction. Optional responses are: Extremely Dissatisfied, Very Dissatisfied, Dissatisfied, Somewhat Satisfied, Satisfied, Very Satisfied, and Extremely Satisfied. From the responses, a scale score from 0 - 100 is calculated, with a higher score indicating greater satisfaction. Change was calculated as postbaseline value - Baseline value so that a positive change indicates improvement.
Baseline and Weeks 12 and 24
Health Resource Utilization: Number of Participants With Visits to a Healthcare Provider
大体时间：Baseline and 24 weeks
Participants completed a questionnaire to assess their health resource utilization (HRU) related to psoriasis. To assess the number of visits to a healthcare provider, participants answered the following questions regarding the past 4 weeks: How many times have you been to any physician's office or urgent care clinic? How many times have you seen a nurse practitioner, a physician assistant, a psychologist, a naturopath, an acupuncturist, a chiropractor, or other healthcare professional (HCP)? The number of participants with one or more visits is reported.
Baseline and 24 weeks
Health Resource Utilization: Number of Participants With Home Healthcare Visits
大体时间：Baseline and 24 weeks
Participants completed a questionnaire to assess their health resource utilization (HRU) related to psoriasis. To assess the number of homecare visits, participants answered the following question regarding the past 4 weeks: How many times have you received care from a health professional in your home? The number of participants with one or more visits is reported.
Baseline and 24 weeks
Health Resource Utilization: Number of Participants Requiring Paid Help With Chores
大体时间：Baseline and 24 weeks
Participants completed a questionnaire to assess their health resource utilization (HRU) related to psoriasis. To assess the number of participants who needed paid help with chores, participants answered the following question regarding the past 4 weeks: How many times have you paid someone to help you do chores around the house (cleaning, maintenance, lawn care)? The number of participants who paid for help one or more times is reported.
Baseline and 24 weeks
Health Resource Utilization: Number of Participants Who Needed Friend or Family Care
大体时间：Baseline and 24 weeks
Participants completed a questionnaire to assess their health resource utilization (HRU) related to psoriasis. Participants answered the following question regarding the past 4 weeks: How many hours have you had a friend or family member take time off work to provide care or transportation? The number of participants who had paid or non-paid help for one or more hours is reported.
Baseline and 24 weeks
Health Resource Utilization: Out of Pocket Expenses
大体时间：Baseline and 24 weeks
Participants completed a questionnaire to assess their health resource utilization (HRU) related to psoriasis. To assess out of pocket expenses, participants answered the following question regarding the past 4 weeks: Not counting study mandated visits, what out-of-pocket expenses did you spend for the management of psoriasis (i.e. costs due to travelling to doctor appointment, hospital or clinic parking costs, alternative medications)?
Baseline and 24 weeks
Health Resource Utilization: Employment Status
大体时间：Baseline and 24 weeks
Participants completed a questionnaire to assess their health resource utilization (HRU) related to psoriasis. Participants were asked their employment status at Baseline and at Week 24.
Baseline and 24 weeks
Health Resource Utilization: Productivity While Working
大体时间：Baseline and 24 weeks
Participants who were employed were asked: How much did your psoriasis affect your productivity while you were working? Possible responses were: a) A great deal; b) Quite a bit; c) Somewhat; d) Minimally; e) Not at all.
Baseline and 24 weeks
Health Resource Utilization: Number of Participants With Missed Hours From Work
大体时间：Baseline and 24 weeks
Participants who were employed answered the following question regarding the past 4 weeks: How many hours per week did you miss from work because of your psoriasis? The number of participants with one or more missed hours of work per week is reported.
Baseline and 24 weeks
Health Resource Utilization: Ability to Perform Daily Activities
大体时间：Baseline and 24 weeks
Participants were asked: How much did your psoriasis affect your ability to do your daily activities or household chores? Possible answers were: a) A great deal; b) Quite a bit; c) Somewhat; d) Minimally; e) Not at all.
Baseline and 24 weeks
Number of Participants With Adverse Events
大体时间：32 weeks
An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: • fatal, • life threatening, • requires in-patient hospitalization or prolongation of existing hospitalization, • results in persistent or significant disability/incapacity, • congenital anomaly/birth defect, and/or • other significant medical hazard.
32 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Amgen

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2011年4月1日

初级完成 (实际的)

2012年12月1日

研究完成 (实际的)

2013年5月1日

研究注册日期

首次提交

2011年2月24日

首先提交符合 QC 标准的

2011年3月10日

首次发布 (估计)

2011年3月11日

研究记录更新

最后更新发布 (实际的)

2017年3月15日

上次提交的符合 QC 标准的更新

2017年2月7日

最后验证

2017年2月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • 20090647

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅